Poster Sessions

Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, Testicular, and Adrenal Cancers
Trials in Progress Poster Session B: Prostate Cancer, Urothelial Carcinoma, and Penile, Urethral, Testicular, and Adrenal Cancers

Friday, February 15: 12:15 PM-1:45 PM and 5:15 PM- 6:15 PM

BOARD B1
Abstract 350: Keynote 057: Phase II trial of Pembrolizumab (pembro) for patients (pts) with high-risk (HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus calmette-guérin (BCG).
First Author: Arjun Balar, MD


BOARD B2
Abstract 351: Randomized phase III trial of adjuvant sequential chemotherapy plus radiotherapy versus adjuvant radiotherapy alone for locally advanced bladder cancer after radical cystectomy: Urothelial carcinoma subgroup analysis.
First Author: Mohamed Zaghloul, MD


BOARD B3
Abstract 505: Penile squamous cell carcinoma is genomically similar to other HPV-driven tumors.
First Author: Jad Chahoud, MD


BOARD B4
Abstract 506: Comprehensive analysis of metastatic seminoma germ cell tumors shows divergent expression of immune-related pathways.
First Author: Tim Nestler, MD


BOARD B5
Abstract 354: Sacituzumab govitecan (IMMU-132) in patients with previously treated metastatic urothelial cancer (mUC): Results from a phase I/II study.
First Author: Scott Tagawa, MD, MS


BOARD B6
Abstract 353: Ramucirumab (RAM) exposure-response (ER) relationship in RANGE: A randomized phase III trial of RAM plus docetaxel (DOC) versus placebo (P) plus DOC in advanced platinum-refractory urothelial carcinoma (UC) patients (pts).
First Author: Ronald De Wit, MD, PhD


BOARD B7
Abstract 507: The PRIMETEST trial: Interim analysis of a phase II trial for primary retroperitoneal lymph node dissection (RPLND) in stage II A/B seminoma patients without adjuvant treatment.
First Author: Peter Albers, MD


BOARD B8
Abstract 508: Malignant pheochromocytoma: A comprehensive genomic profiling study.
First Author: Gennady Bratslavsky, MD


BOARD B9
Abstract 409: Fierce-21: Phase II study of vofatmab (B-701), a selective inhibitor of FGFR3, as salvage therapy in metastatic urothelial carcinoma (mUC).
First Author: Andrea Necchi, MD, MD


BOARD B10
Abstract 355: Gemcitabine-carboplatin (GCb) versus gemcitabine-oxaliplatin (GemOx) in cisplatin un-fit advanced urothelial carcinoma: Randomized phase II study (COACH Study).
First Author: Jae-Lyun Lee, MD


BOARD B11
Abstract 356: Long-term outcomes of hypoxia modification in bladder preservation: Update from BCON trial.
First Author: Yee Pei Song, FRCR, MBBCh, MRCP


BOARD B12
Abstract 509: Whole genome and transcriptome analysis (WGTA) of metastatic adrenocortical carcinoma (mACC).
First Author: Jean-Michel Lavoie, MD


BOARD B13
Abstract 510: Outcome of men with relapses after adjuvant BEP for clinical stage I nonseminoma.
First Author: Stefanie Fischer, MD


BOARD B14
Abstract 112: Outcomes in a cohort of patients with a Gleason Score 6 on radical prostatectomy specimen.
First Author: Elodie Le Bihan, resident


BOARD B15
Abstract 113: Hospitalization after prostate biopsy in Iceland: Results from a nationwide study.
First Author: Birgitta Ólafsdóttir


BOARD B16
Abstract 114: The impact of Charlson Comorbidity Index on survival outcomes in men with prostate cancer who underwent definitive prostate radiotherapy.
First Author: Ahmed Ghanem, MD, MS


BOARD B17
Abstract 115: Racial disparities in late-stage prostate cancer: A SEER database analysis 2005–2015.
First Author: Jianqing Lin, MD


BOARD B18
Abstract 116: The cost of prostate cancer care to society and to patients in the United States.
First Author: Nicholas Zaorsky, MD


BOARD B19
Abstract 117: Significance of tertiary pattern 5 in patients with gleason score 7 after radical prostatectomy.
First Author: Jiakun Li


BOARD B20
Abstract 118: Overall survival outcomes with the use of adjuvant chemotherapy, radiation therapy and hormone therapy in high risk, very high risk and node positive prostate cancer post radical prostatectomy- A NCDB analysis.
First Author: Alina Basnet, MBBS, MD


BOARD C1
Abstract 119: State rurality does not increase risk of prostate cancer death.
First Author: Alexander Anderson, Medical Doctor


BOARD C2
Abstract 120: Feasibility of robot-assisted radical prostatectomy in high elderly patients: Comparative analysis of the perisurgical/oncological outcomes with younger patients.
First Author: Noriyoshi Miura, PhD, MD


BOARD C3
Abstract 121: Racial differences in long-term prostate cancer specific mortality following conservative management for low-risk prostate cancer: A population-based study.
First Author: Grace Lu-Yao


BOARD C4
Abstract 122: Predictors of prostate bed nodule on MRI in patients with rising PSA after radical prostatectomy.
First Author: Nicola Nasser, MD, PhD


BOARD C5
Abstract 123: Intraductal carcinoma of the prostate in prostate biopsy samples: Correlation with pathological features after radical prostatectomy and prognostic value in high-risk prostate cancer patients.
First Author: Sha Zhu, MD


BOARD C6
Abstract 124: Risk of recurrence in patients with positive surgical margin at apex only versus other locations after radical prostatectomy.
First Author: Masashi Kato


BOARD C7
Abstract 125: Increasing utilization of multi-parametric magnetic resonance imaging in prostate cancer active surveillance.
First Author: Avinash Maganty, MD


BOARD C8
Abstract 126: Radiogenomic characterization of multifocal prostate cancer.
First Author: Simpa Salami, MD, MPH


BOARD C9
Abstract 127: The value of transperineal prostate apical zone biopsy in predicting urethral or apical margin status after radical prostatectomy in prostate cancer.
First Author: Jindong Dai


BOARD C10
Abstract 128: The validation of the 2014 International Society of Urological Pathology (ISUP) grading system for patients with high-risk prostate cancer: A single-center retrospective study.
First Author: Jiandong Liu


BOARD C11
Abstract 129: Marijuana use history in patients presenting with localized prostate cancer.
First Author: Romaine Nichols, MD


BOARD C12
Abstract 130: Reduced risk of prostate cancer in a cohort of Lithuanian diabetes mellitus patients.
First Author: Ausvydas Patasius


BOARD C13
Abstract 131: Late toxicity described using patient reported outcomes measures (PROMS) in men treated with salvage radiation following primary high intensity focal ultrasound (HIFU) for localized prostate cancer.
First Author: Reena Davda


BOARD C14
Abstract 132: Genomic findings in adenocarcinoma of the urinary bladder.
First Author: Oleg Shapiro, FACS, MD


BOARD C15
Abstract 133: Prostate cancer in young men: Our experience.
First Author: João Barreira, MD


BOARD C16
Abstract 134: Experience of a single Brazilian center on PSMA-PET in biochemical recurrence in patients with prostate cancer.
First Author: Paulo Lages, MD


BOARD C17
Abstract 135: The effect of urologic oncology fellowship training on type and yield of prostate biopsy.
First Author: Molly DeWitt-Foy, MD


BOARD C18
Abstract 288: Utilization and outcomes of surgical castration in comparison to medical castration in metastatic prostate cancer.
First Author: Rohan Garje, MD


BOARD C19
Abstract 289: The prognostic value of mid-treatment prostate-specific antigen level in patients receiving salvage radiotherapy.
First Author: Jason Homza, MS


BOARD C20
Abstract 290: AUCtox: A new method to evaluate the safety of anticancer drugs in metastatic prostate cancer.
First Author: Vincent Launay-Vacher, PharmD


BOARD C21
Abstract 291: German health service research with the focus on effectiveness of secondary-antiandrogen deprivation therapy (s-ADT) in prostate cancer patients with buserelin in daily practice.
First Author: Gerson Luedecke, MD


BOARD C22
Abstract 292: Exploratory study of prognostic factors in mCRPC patients who administered enzalutamide focusing on early PSA decline and PSA kinetics at PSA progression: Results of retrospective multicenter study.
First Author: Yoshiyuki Miyazawa, MD


BOARD D1
Abstract 293: Enzalutamide versus flutamide for castration-resistant prostate cancer after combined androgen blockade therapy with bicalutamide: A retrospective study.
First Author: Kosuke Hamada, M.D.


BOARD D2
Abstract 294: Alkaline phosphatase (ALP) value at diagnosis of CRPC and response to primary androgen deprivation therapy may predict metastasis in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC).
First Author: Keiichiro Mori, M.D.


BOARD D3
Abstract 295: A survey to determine patients’ (pts) opinions of a clinical trial (CT) comparing intermittent (int) versus continuous (cont) androgen receptor signaling inhibitor (ARSi) therapy for the treatment of advanced prostate cancer.
First Author: Cameron Phillips, MD


BOARD D4
Abstract 296: Effect of IL-6 and related mediators on resistance to abiraterone acetate (abi) and enzalutamide (enza) in patients with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Jacob Adashek, BA


BOARD D5
Abstract 297: Drug-drug interaction (DDI) of darolutamide with cytochrome P450 (CYP) and P-glycoprotein (P-gp) substrates: Results from clinical and in vitro studies.
First Author: Christian Zurth, PhD


BOARD D6
Abstract 298: Timing of docetaxel chemotherapy and impact on outcomes in metastatic castrate-resistant prostate cancer (MCRPC).
First Author: Alastair Thomson, BM MRCP FRCR PGCE


BOARD D7
Abstract 299: The oral α and β tubulin inhibitor, VERU-111, for the treatment of metastatic castration-resistant and androgen blocking agent-resistant prostate cancer in nonclinical toxicity studies.
First Author: Robert Getzenberg, PhD


BOARD D8
Abstract 300: Prognostic significance of lactate dehydrogenase-5 expression in patients with prostate cancer treated with androgen deprivation therapy and androgen receptor axis-targeted agents.
First Author: Wataru Fukuokaya, M.D.


BOARD D9
Abstract 301: Preclinical evaluation of AMG 160, a next-generation bispecific T cell engager (BiTE®) targeting the prostate-specific membrane antigen PSMA for metastatic castration-resistant prostate cancer (mCRPC).
First Author: Julie Bailis, PhD


BOARD D10
Abstract 302: The effect of androgen receptor splice variant 7 on the growth of castration-resistant prostate cancer and the efficacy of taxane chemotherapy.
First Author: Yasuomi Shimizu, M.D.


BOARD D11
Abstract 303: Abiraterone acetate plus prednisone/prednisolone compared with enzalutamide in metastatic castration resistant prostate cancer before or after chemotherapy: A retrospective study of real-world data (ACES).
First Author: Prantik Das, MD


BOARD D12
Abstract 304: Prostate cancer (PCa) incidence and severity in 821 hypogonadal men with and without testosterone therapy (TTh) in a controlled, observational registry implying more than 7,000 patient-years.
First Author: Ahmad Haider


BOARD D13
Abstract 305: Next generation sequencing of primary prostate cancer tumors to reveal potentially actionable opportunities for clinical management: The UNC experience.
First Author: Daniel Crona, PharmD, PhD


BOARD D14
Abstract 306: Biochemichal recurrence in prostate cancer after salvage surgery in correlation to the site of reccurrent disease.
First Author: David Pfister


BOARD D15
Abstract 307: Intermittent bicalutamide in recurrent non-metastatic castrate sensitive prostate cancer: A single institution experience.
First Author: Mark Prentice, FRCR, MBBCh, MRCP


BOARD D16
Abstract 308: The hematologic parameters in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.
First Author: Onal Cem, Prof


BOARD D17
Abstract 309: Patients with an extremely high prostate-specific antigen at prostate cancer diagnosis: A single institution analysis.
First Author: Qian Qin, MD


BOARD D18
Abstract 310: PRINT: Prostate cancer intensive, non-cross reactive therapy for CRPC—Early observations of feasibility and efficacy.
First Author: Bobby Liaw, MD


BOARD D19
Abstract 311: Protection of prostate cancer cells from GSK-3β-induced oxidative stress by Il-8 through activating the mTOR signaling pathway.
First Author: Yi Sun, Doctor


BOARD D20
Abstract 312: Integration of radium-223 dichloride (Xofigo) into clinical practice for the treatment of castration-resistant prostate cancer.
First Author: Catherine Doyle, BS


BOARD D21
Abstract 313: The value of AKR1C3 in predicting the therapeutic efficacy of abiraterone for patients with metastatic castration-resistant prostate cancer.
First Author: Jinge Zhao


BOARD D22
Abstract 314: Clinical significance of AR amplification from CF DNA among Japanese castration-resistant prostate cancer patients.
First Author: Shinichi Sakamoto


BOARD E1
Abstract 315: The association of PSA levels and survival outcomes in patients with chemotherapy-naïve, castration-resistant prostate cancer (CRPC) who were treated with androgen receptor signaling axis targeting agent (ARAT): A Japanese cohort study.
First Author: Tatsuya Shimomura, MD


BOARD E2
Abstract 316: The outcome of loco-regional radiotherapy in metastatic castration-resistant prostate cancer patients treated with abiraterone acetate.
First Author: Berna Yildirim


BOARD E3
Abstract 317: Regional variations in online education test performance for prostate cancer care.
First Author: Hamsa Jaganathan, PhD


BOARD E4
Abstract 318: Clinical drivers for imaging testing in nonmetastatic castration-resistant prostate cancer: May they be optimized?—Data of “IDENTIFICA” study.
First Author: Eduardo Useros Rodrìguez


BOARD E5
Abstract 319: Continuous infusion 5-fluorouracil (5FU) as a novel treatment for heavily pretreated prostate cancer patients: An update.
First Author: Charlotte Manogue


BOARD E6
Abstract 320: Genomic changes of AR in ctDNA prior to enzalutamide in men with mCRPC after abiraterone acetate.
First Author: Leta Ko


BOARD E7
Abstract 321: Germline heterozygous BLM mutations and prostate cancer risk.
First Author: Elisa Ledet, PhD


BOARD E8
Abstract 322: Genetic testing patterns for homologous recombination repair (HRR) alterations in patients with metastatic prostate cancer (mPC): An assessment at the University of Rochester (UR).
First Author: Kerry Schaffer, MD


BOARD E9
Abstract 323: Clinical outcomes of a Dutch prospective observational registry of metastatic castration resistant prostate cancer (mCRPC) patients treated with radium-223 (Ra-223).
First Author: Rebecca Louhanepessy, BA


BOARD E10
Abstract 324: A novel CD3xPSMA bispecific antibody for efficient T cell mediated killing of prostate tumor cells with minimal cytokine release.
First Author: Starlynn Clarke, PhD


BOARD E11
Abstract 325: Retrospective review of 11C-choline detected thoracic lesions in prostate cancer.
First Author: Muneeb Rehman, MD


BOARD E12
Abstract 326: Synergistic effects of the PARP inhibitor olaparib and pharmacological ascorbate in castration-resistant prostate cancer.
First Author: Nicolas Gordon


BOARD E13
Abstract 327: Prostatectomy in men with clinically positive lymph nodes.
First Author: Stephen Ryan, MD


BOARD E14
Abstract 357: Multidimensional flow characterization of circulating immune cells in cisplatin-resistant metastatic urothelial cancer (mUC) patients (pts) treated with pembrolizumab (P) with or without acalabrutinib (acala).
First Author: Tian Zhang, MD


BOARD E15
Abstract 358: BMS-986205, an indoleamine 2, 3-dioxygenase 1 inhibitor (IDO1i), in combination with nivolumab (nivo): Updated safety across all tumor cohorts and efficacy in advanced bladder cancer (advBC).
First Author: Jason Luke, MD, FACP


BOARD E16
Abstract 359: Cell-free DNA (cfDNA) whole genome bisulfite sequencing in patients with muscle-invasive bladder cancer patient treated with cystectomy with curative intent.
First Author: Yi-Tsung Lu, MD


BOARD E17
Abstract 360: Evaluation of submicron particle docetaxel directly injected into uro-oncologic xenografts.
First Author: Gere Dizerega, MD


BOARD E18
Abstract 361: Cancer-related fatigue in carcinoma urinary bladder patients receiving chemotherapy: A single institutional study from northern India.
First Author: Vineet Talwar, MD, MBBS


BOARD E19
Abstract 362: Re-examining an old trend: The association of human papillomavirus and bladder cancer.
First Author: Lael Reinstatler, MD, MPH


BOARD E20
Abstract 363: Economic burden of select adverse events (AEs) in patients (Pts) with advanced urothelial cancer (aUC) treated with first-line (1L) systemic therapy.
First Author: Petros Grivas, MD, PhD


BOARD E21
Abstract 364: Bladder-preserving therapy using a real-time tumor-tracking radiotherapy system for muscle-invasive bladder cancer.
First Author: Haruka Miyata


BOARD E22
Abstract 365: Interim analysis of ibrutinib plus paclitaxel for patients with metastatic urothelial carcinoma previously treated with platinum-based chemotherapy.
First Author: Daniel Castellano, MD


BOARD F1
Abstract 366: Decreasing ureteral stent duration following radical cystectomy decreases readmissions and urinary infectious complications.
First Author: Hamza Beano, MD


BOARD F2
Abstract 367: Role of adjuvant chemotherapy in advanced stage upper urinary tract urothelial carcinoma after radical nephroureterectomy: A competing risk analysis.
First Author: Minyong Kang


BOARD F3
Abstract 368: A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS).
First Author: Thomas Powles, MD, PhD, FCRP


BOARD F4
Abstract 369: Hyperprogressive disease (HPD) in genitourinary (GU) cancer patients treated with PD-1/PD-L1 inhibitors.
First Author: Inhwan Hwang


BOARD F5
Abstract 370: ATM mutation is associated with shorter overall survival in relapsed/advanced urothelial cancer.
First Author: Ming Yin, MD


BOARD F6
Abstract 371: Distinct genomic hallmarks exist between metastatic upper and lower tract urothelial carcinoma.
First Author: Brian Winters, MD


BOARD F7
Abstract 372: Comparing costs of radical cystectomy versus trimodal therapy for patients diagnosed with localized muscle-invasive bladder cancer.
First Author: Mohamed Ray-Zack, MBBS


BOARD F8
Abstract 373: Comparing radical cystectomy with trimodal therapy for patients diagnosed with bladder cancer: Critical assessment of statistical methodology and interpretation of observational data.
First Author: Mohamed Ray-Zack, MBBS


BOARD F9
Abstract 374: The role of adjuvant chemotherapy for pT2-4 upper urinary tract urothelial cancer: Exploratory analysis of large multi-institutional study (JCOG1110A).
First Author: Junichi Inokuchi, MD, PhD


BOARD F10
Abstract 375: Prognostic significance of history of nonmuscle invasive bladder cancer in patients with muscle invasive bladder cancer treated with neoadjuvant chemotherapy followed by surgery.
First Author: Yongjune Lee, MD


BOARD F11
Abstract 376: Comparing clinical outcomes between patients with urothelial carcinoma who treated neoadjuvant chemotherapy by gemcitabine-cisplatin and dose-dense MVAC.
First Author: Yongjune Lee, MD


BOARD F12
Abstract 377: Mature results from EV-101: A phase I study of enfortumab vedotin in patients with metastatic urothelial cancer (mUC).
First Author: Jonathan Rosenberg, MD


BOARD F13
Abstract 378: Molecular profiling of aggressive variant urothelial carcinoma.
First Author: Chethan Ramamurthy, MD


BOARD F14
Abstract 379: Circulating tumor cell (CTC) enumeration in patients (pts) with metastatic genitourinary (mGU) tumors treated in a phase I study of cabozantinib and nivolumab (CaboNivo) +/- ipilimumab (CaboNivoIpi).
First Author: Zishuo Hu


BOARD F15
Abstract 380: Patient-reported symptoms and impacts of locally advanced or metastatic urothelial cancer (la/mUC) after chemotherapy followed by a PD-1/PD-L1 checkpoint inhibitor (CPI).
First Author: Manasee Shah


BOARD F16
Abstract 381: Treatment (tx) characteristics of patients (pts) with locally advanced or metastatic urothelial cancer (mUC) receiving atezolizumab (atezo) monotherapy in United States clinical practice.
First Author: Shivani Mhatre, PhD


BOARD F17
Abstract 382: Presurgical anemia as a predictor of relapse and survival in bladder carcinoma treated with cystectomy.
First Author: Alvaro Pinto, MD, PhD


BOARD F18
Abstract 383: Risk for vascular thromboembolic events (VaTEs) in patients (pts) with advanced urinary tract cancer (aUTC) treated with chemotherapy.
First Author: Aristotelis Bamias, MD


BOARD F19
Abstract 384: Assessment of the diagnostic value of microsatellite instability in the urine of bladder cancer patients.
First Author: Hussein Khaled, MD


BOARD F20
Abstract 385: A phase II trial to evaluate pemetrexed clinical responses in relation to tumor methylthioadenosine phosphorylase (MTAP) gene status in patients with previously treated metastatic urothelial carcinoma.
First Author: Omar Alhalabi, MD


BOARD F21
Abstract 386: Prior hepatitis B infection is a novel risk factor for bladder cancer.
First Author: Lael Reinstatler, MD, MPH


BOARD F22
Abstract 387: Impact of sarcopenia on kidney function during neoadjuvant chemotherapy and post cystectomy complications in patients treated for localized muscle-invasive bladder cancer.
First Author: Pierre Regnier, M.D.


BOARD G1
Abstract 388: NKTR-214 + nivolumab in first-line advanced/metastatic urothelial carcinoma (mUC): Updated results from PIVOT-02.
First Author: Arlene Siefker-Radtke, MD


BOARD G2
Abstract 389: Treatment of locally advanced or metastatic urothelial carcinoma: Analysis of expert and community healthcare provider practice trends.
First Author: Kristen Rosenthal, PhD


BOARD G3
Abstract 390: Inflammatory markers at baseline (C1) and cycle 3 (C3) and their association with clinical outcomes in urothelial cancer patients (pts) treated with immunotherapy (IO).
First Author: Julie Shabto, BA


BOARD G4
Abstract 391: First survival outcomes and additional secondary analyses from PURE-01: Pembrolizumab (pembro) before radical cystectomy (RC) in muscle-invasive urothelial bladder carcinoma (MIBC).
First Author: Andrea Necchi, MD, MD


BOARD G5
Abstract 392: Real-world trends in first-line checkpoint inhibitor use (CPI) in advanced urothelial cell carcinoma (aUC).
First Author: Ravi Parikh, MD


BOARD G6
Abstract 393: Impact of Aurora kinase A and B expression on response to neoadjuvant chemotherapy and patient outcome in muscle-invasive bladder cancer (MIBC).
First Author: Earle Burgess, MD


BOARD G7
Abstract 394: Long-term outcomes in elderly patients (pts) from IMvigor210: atezolizumab (atezo) in metastatic urothelial cancer (mUC).
First Author: Arjun Balar, MD


BOARD G8
Abstract 395: Trends in checkpoint inhibitor therapy for advanced urothelial cell carcinoma (aUC) at the end of life: Insights from real-world practice.
First Author: Ravi Parikh, MD


BOARD G9
Abstract 396: Identification of novel targets in non-muscle invasive bladder cancer: A systems biology approach.
First Author: Robin Osterhout, PhD


BOARD G10
Abstract 397: Association of next generation sequencing characteristics of MIBC specimens with clinical outcomes: The USC experience.
First Author: Arnab Basu, MBBS, MPH


BOARD G11
Abstract 398: Circulating cellular biomarkers associated with delayed time to progression among bladder cancer patients treated with immune checkpoint inhibitors.
First Author: Vadim Koshkin, MD


BOARD G12
Abstract 399: Non-urothelial bladder cancer: Genomic alterations and patient outcomes.
First Author: Fern Anari, MD


BOARD G13
Abstract 400: Characterization of genomic alterations as biomarkers of immune checkpoint inhibitor (ICI) response in metastatic urothelial carcinoma (mUC).
First Author: Matthew Labriola, MD


BOARD G14
Abstract 401: Serial ctDNA tracking reveals clonal evolution dynamics in advanced urothelial carcinoma (UC).
First Author: Dario Villamar, MD


BOARD G15
Abstract 402: Comparative analyses of trends and survival in patients with urothelial versus nonurothelial bladder carcinoma: National Cancer Database (NCDB) analysis.
First Author: Jeanny Aragon-Ching, MD, FACP


BOARD G16
Abstract 403: Carcinomas of the renal pelvis, ureters, and urinary bladder arise by similar carcinogenic pathways: A pathoepidemiological analysis.
First Author: Amanda Nizam, MD


BOARD G17
Abstract 404: Clinical impact of gemcitabine mono-maintenance versus best supportive care after first-line gemcitabine with platinum in patients with metastatic urothelial carcinoma.
First Author: Seung-Hwan Lee, MD


BOARD G18
Abstract 405: Is the occurrence of higher adverse effects associated with better oncological outcome in metastatic urothelial carcinoma patients treated with pembrolizumab?
First Author: Nozomi Hayakawa, MD


BOARD G19
Abstract 406: A phase I study to assess the safety and tolerability of intravesical pembrolizumab in recurrent non-muscle invasive bladder cancer (NMIBC).
First Author: Victoria Woodcock, MBBS


BOARD G20
Abstract 407: Characterization of actionable genetic alterations to guide targeted therapy for metastatic urothelial carcinoma.
First Author: Nima Almassi, MD


BOARD G21
Abstract 408: Analysis of the National Cancer Data Base (NCDB) on impact and trend of neoadjuvant chemotherapy in upper urinary tract urothelial cancer.
First Author: Rashad Khan, MD


BOARD H1
Abstract 410: The role of phosphoglycerate mutase 2 in UM-UC3 bladder cancer cell metabolism.
First Author: Ryan Didde, BS


BOARD H2
Abstract 411: FGFR3 mutation as a prognostic indicator in patients with urothelial carcinoma: A systematic review and meta-analysis.
First Author: Sidra Khalid, MD


BOARD H3
Abstract 412: Serum cytokeratin 19 fragments: A novel preoperative prognostic marker in patients with upper urinary tract urothelial carcinoma.
First Author: Yuki Endo, MD


BOARD H4
Abstract 413: Digital holography can differentiate between bladder cancer grades.
First Author: Miki Haifler


BOARD H5
Abstract 414: Novel perioperative parameters-based nomograms for survival outcomes in upper tract urothelial carcinoma after radical nephroureterectomy.
First Author: Ping Tan, Ph.D


BOARD H6
Abstract 415: Development of myeloid-derived suppressor cells (MDSC) targeted therapy for the treatment of cisplatin-resistant bladder cancer.
First Author: Yuji Takeyama, M.D.


BOARD H7
Abstract 416: Analysis of EGFR mutant upper tract and bladder urothelial carcinoma (UC) reveals distinct mutational landscape.
First Author: Russell Madison, BA


BOARD H8
Abstract 417: Clinical impact of Bacillus Calmette-Guérin (BCG) Therapy on prognosis in patients with carcinoma in situ (CIS) of the upper urinary tract: A retrospective comparison with nephroureterectomy.
First Author: Takahiro Yoneyama


BOARD H9
Abstract 418: Radiotherapy-induced immunogenic effects in bladder cancer.
First Author: Richard Walshaw, MBChB MRCP FRCR


BOARD H10
Abstract 419: Predictive value of fibroblast growth factor receptor (FGFR) mutations and gene fusions on anti-PD-(L)1 treatment outcomes in patients (pts) with advanced urothelial cancer (UC).
First Author: Ademi Santiago-Walker, PhD


BOARD H11
Abstract 420: Analysis of FGFR alterations from circulating tumor DNA (ctDNA) and Tissue in a phase II trial of erdafitinib in urothelial carcinoma (UC).
First Author: Ademi Santiago-Walker, PhD


BOARD H12
Abstract 421: The impact of histologic variants of urothelial carcinoma on clinical outcomes following trimodal bladder-preserving therapy.
First Author: Yoshiyuki Nagumo


BOARD H13
Abstract 422: Randomized phase I trial of pembrolizumab with neo-adjuvant versus concomitant stereotactic body radiotherapy in metastatic urothelial carcinoma: Clinical and translational results.
First Author: Gillian Vandekerkhove, BSc, MSc


BOARD H14
Abstract 423: Association of the commensal urinary microbiome with response to Bacillus Calmette-Guérin (BCG) immunotherapy in nonmuscle invasive bladder cancer.
First Author: Randy Sweis, MD


BOARD H15
Abstract 424: Predictive role of CT texture analysis in patients with metastatic urothelial cancer treated with PD-1/PD-L1 inhibitors.
First Author: Francesco Alessandrino, MD


BOARD H16
Abstract 425: Avelumab treatment for metastatic urothelial carcinoma in the phase Ib JAVELIN Solid Tumor Study: Updated safety and efficacy analysis with ≥ two years of follow-up.
First Author: Andrea Apolo, MD


BOARD H17
Abstract 426: Outcomes of patients following dose-dense neoadjuvant chemotherapy for muscle-invasive bladder cancer: Implications for organ-sparing strategies.
First Author: Clement Dumont, MD


BOARD H18
Abstract 427: Prognostic value of genomic alterations in DNA damage response (DDR) genes in relapsed/advanced bladder cancer (BCa).
First Author: Ming Yin, MD


BOARD H19
Abstract 428: Avelumab treatment in metastatic urothelial carcinoma: Post-hoc analysis of high-risk populations in the phase Ib JAVELIN Solid Tumor Study.
First Author: Andrea Apolo, MD


BOARD H20
Abstract 429: Avelumab treatment in metastatic urothelial carcinoma: Association between early response and durable outcomes in the phase Ib JAVELIN Solid Tumor Study.
First Author: Manish Patel, MD


BOARD J1
Abstract 430: Clinical outcomes of muscle-invasive bladder cancer patients with hydronephrosis treated with tetra-modality bladder sparing therapy incorporating consolidative partial cystectomy.
First Author: Toshiki Kijima, MD, PhD


BOARD J2
Abstract 431: Impact of bone metastasis on clinical outcomes in metastatic urothelial bladder cancer (mUC) for patients treated with first-line platinum-based chemotherapy.
First Author: Jamila Rir Omar


BOARD J3
Abstract 432: First-line PD1/PD-L1 inhibitors for platinum-ineligible advanced urothelial carcinoma (UC).
First Author: Archana Agarwal, MBBS


BOARD J4
Abstract 433: Association between stromal/TGF-β/EMT gene expression signature and response to pembrolizumab monotherapy in cisplatin-ineligible patients with locally advanced (unresectable) or metastatic urothelial carcinoma.
First Author: Petros Grivas, MD, PhD


BOARD J5
Abstract 434: The cost of obesity in radical cystectomy.
First Author: Melissa Huynh, MD


BOARD J6
Abstract 435: Impact of concurrent medications on outcomes with PD1/PD-L1 inhibitors for metastatic urothelial carcinoma.
First Author: Archana Agarwal, MBBS


BOARD J7
Abstract 436: Blood myeloid derived suppressor cells (MDSC) in metastatic urothelial carcinoma (mUC) are correlated with neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS).
First Author: Iris Sheng, MD


BOARD J8
Abstract 437: Correlation of myeloid-derived suppressor cells (MDSC) with pathologic complete response (pCR), recurrence free survival (RFS), and overall survival (OS) in patients with urothelial carcinoma (UC) undergoing cystectomy.
First Author: Jaleh Fallah, MD


BOARD J9
Abstract 438: Alterations of DNA damage response (DDR) genes correlate with favorable response and overall survival (OS) in anti-PD-1/PD-L1-treated advanced urothelial cancer (UC).
First Author: Monika Joshi, MD, MRCP


BOARD J10
Abstract 439: Identifying factors associated with poor genitourinary cancer clinical trial accrual using a novel data extraction algorithm.
First Author: Kristian Stensland, MD, MPH


BOARD J11
Abstract 440: A comparison of pathologic and intermediate term oncologic outcomes following open and robotic radical cystectomy.
First Author: Janet Kukreja, MD, MPH


BOARD J12
Abstract 441: Neoadjuvant chemotherapy utilization in muscle-invasive bladder cancer: Increasing yet inappropriate use?
First Author: Yaw Nyame, MD, MBA


BOARD J13
Abstract 442: Tumor mutational burden (TMB) and BCG responsiveness in high-risk non-muscle invasive bladder cancer (NMIBC).
First Author: Diogo Bastos, MD


BOARD J14
Abstract 443: Muscle invasive bladder cancer (MIBC) demonstrates neoadjuvant cisplatin-based chemotherapy (NAC) related changes in molecular subtype and immune infiltration.
First Author: Samuel Funt, MD


BOARD J15
Abstract 444: The timing from perioperative chemotherapy and disease recurrence could have clinical impact on survival in bladder cancer patients treated with salvage chemotherapy.
First Author: Eiji Kikuchi, MD


BOARD J16
Abstract 445: Relationships between anticancer effects and serum gemcitabine levels, human antigen-R expression, and their combination in advanced urothelial cancer treated with gemcitabine and platinum agents.
First Author: Yuji Sagara


BOARD J17
Abstract 446: Intra-vesical therapy using 4N1K-peptide in bladder cancer and its effects on tumor growth and angiogenesis.
First Author: Yasuyoshi Miyata


BOARD J18
Abstract 447: Analysis of real-world PD-L1 testing in patients with urothelial carcinoma.
First Author: Gabriel Krigsfeld


BOARD J19
Abstract 448: Hyperprogressive disease in patients with metastatic genitourinary tumors treated with immune checkpoint inhibitors.
First Author: Cristina Suárez, MD, PhD


BOARD J20
Abstract 449: Potential markers of response and resistance to programmed cell death-1 blockade in first-line therapy of cisplatin-inilegible advanced urothelial cancer.
First Author: Alberto Carretero-González


BOARD J21
Abstract 450: Genomic profiling of variant urinary tract tumor histologies.
First Author: Amin Nassar


BOARD J22
Abstract 451: Defining “platinum-ineligible” patients with metastatic urothelial cancer (mUC).
First Author: Shilpa Gupta, MD


BOARD K1
Abstract 452: Metabolic syndrome and upper tract urothelial carcinoma: A retrospective analysis from a large Chinese cohort.
First Author: Hang Xu


BOARD K2
Abstract 453: SPEAR-Bladder (Study informing treatment Pathway dEcision in bladder cAnceR): Influence of treatment sequencing on time to treatment failure and overall survival in the United States.
First Author: Gurjyot Doshi, MD


BOARD K3
Abstract 454: Circulating cell-free methylated DNA (cfmeDNA) to predict postoperative recurrence in patients with muscle-invasive bladder cancer (MIBC).
First Author: Pier Nuzzo, MD


BOARD K4
Abstract 455: Activity of RX-3117, an oral antimetabolite nucleoside, in subjects with advanced urothelial cancer: Preliminary results of a phase IIa study.
First Author: Nicholas Salgia, None


BOARD K5
Abstract 456: Lentiviral interferon: A novel method for gene therapy in bladder cancer.
First Author: Sharada Mokkapati, Ph.D.


BOARD K6
Abstract 457: Genomic concordance between profiling of circulating tumor DNA (ctDNA) and matched tissue in metastatic urothelial carcinoma.
First Author: Gillian Vandekerkhove, BSc, MSc


BOARD K7
Abstract 458: Fibroblast growth factor receptor status and response to immune checkpoint inhibition in metastatic urothelial cancer.
First Author: Tracy Rose, MD


BOARD K8
Abstract 459: Invasive urothelial cancer (iUC) with FGFR3 hotspot mutation/fusion (FGFR3+): A molecularly and clinically distinctive entity?
First Author: Jose Mauricio Mota, MD, PhD


BOARD K9
Abstract 460: Analysis of HER2 mutant bladder urothelial carcinomas reveals unique mutational signature.
First Author: Luke Juckett


BOARD K10
Abstract 461: Regulation of stem cell-like phenotype and response to chemotherapy in bladder cancer by beta-arrestins.
First Author: Martin Hennig


BOARD K11
Abstract 462: Let-7f microRNA expression within established bladder cancer subtypes and upregulation with recombinant interferon-alpha.
First Author: Vikram Narayan, M.D.


BOARD K12
Abstract 463: Assessment of the androgen receptor (AR) activity score versus AR expression in muscle invasive bladder cancer (MIBC).
First Author: Paulo Bergerot, MD


BOARD K13
Abstract 464: Comparison of investigator-initiated and industry-initiated trials in Canada and other countries.
First Author: Bryan Wong


BOARD K14
Abstract 465: Evaluation of prognostic effects of MSI, PD-L1 and TIL in resected bladder cancer.
First Author: Deniz Tural, MD


BOARD K15
Abstract 466: Urine cell flow cytometry analysis of PD-L1 expression and DNA content for bladder cancer.
First Author: Pin-I Chen, PhD


BOARD K16
Abstract 467: Effect of concurrent beta-blocker (BB) use in patients receiving immune checkpoint inhibitors for metastatic urothelial (mUC) and renal cell carcinomas (mRCC).
First Author: Vaibhav Patel, MD


BOARD K17
Abstract 468: Small cell bladder carcinoma: Single institution experience.
First Author: Megan Wheelden, MD


BOARD K18
Abstract 469: Sequential intravesical gemcitabine and docetaxel in the treatment of BCG-naive patients with non-muscle invasive bladder cancer.
First Author: Lewis Thomas, M.D.


BOARD K19
Abstract 470: Identification of gene expression determinants of radiosensitivity in bladder cancer (BCa) cell lines.
First Author: Thirunavukkarasu Sitalaximi, PhD


BOARD K20
Abstract 471: Results from a phase I/Ib trial of enzalutamide and gemcitabine and cisplatin in metastatic bladder cancer (mBC).
First Author: Shilpa Gupta, MD


BOARD K21
Abstract 472: Association between immune-related adverse events (irAEs) and clinical outcomes (CO) in advanced urothelial cancer patients (pts) treated with immunotherapy (IO).
First Author: Julie Shabto, BA


BOARD K22
Abstract 473: Sites of metastases (mets) and their association with clinical outcomes (CO) in urothelial cancer patients (pts) treated with immunotherapy (IO).
First Author: Julie Shabto, BA


BOARD L1
Abstract 474: Germline alterations in urothelial carcinoma (UC) patients with family history of UC.
First Author: Amin Nassar


BOARD L2
Abstract 475: Comparative analysis of biopsy proven lymph node positive bladder cancer patients to those with biopsy proven lymph node negative disease prior treatment.
First Author: Amy Lim, M.D, PhD


BOARD L3
Abstract 476: Validated five-factor prognostic model for survival of patients (pts) with metastatic urothelial carcinoma (mUC) receiving different post-platinum PD-L1 inhibitors.
First Author: Guru Sonpavde, MD


BOARD L4
Abstract 477: National trends and pathologic outcomes of neoadjuvant chemotherapy among patients with micropapillary variant urothelial carcinoma of the bladder.
First Author: Juan Javier-Desloges, MD


BOARD L5
Abstract 478: Health-Related Quality of Life (HRQOL) reporting in phase III randomized controlled trials (RCTs) of metastatic prostate adenocarcinoma (mPCa) and urothelial carcinoma (mUC).
First Author: Di Jiang, MD, FRCPC


BOARD L6
Abstract 479: Impact of pure versus mixed metastatic urothelial carcinoma (mUC) histology on response with immune checkpoint inhibitors (ICIs).
First Author: Archana Agarwal, MBBS


BOARD L7
Abstract 480: Sarcopenia in bladder cancer patients is an unmodifiable outcomes predictor.
First Author: Gregory Barton, MD


BOARD L8
Abstract 481: Durable clinical benefit from combination ipilimumab (IPI) and nivolumab (NIVO) in anti-PD-1 therapy resistant, platinum resistant metastatic urothelial carcinoma (mUC).
First Author: Niamh Keegan


BOARD L9
Abstract 482: Comprehensive radiogenomics analysis of qualitative and quantitative features of cross-sectional imaging in the TCGA project in MIBC.
First Author: Seth Lerner, MD


BOARD L10
Abstract 483: Plasmacytoid variant urothelial carcinoma: Clinicopathologic outcomes and experience with neoadjuvant chemotherapy.
First Author: Kyle Ericson, MD


BOARD L11
Abstract 484: Contemporary analysis of ureteroenteric strictures after open and robot-assisted radical cystectomy: A population-based study.
First Author: Neal Patel


BOARD L12
Abstract 485: The nonsurgical management of upper tract urothelial carcinoma: A role for active surveillance?
First Author: Jamil Syed, MD


BOARD L13
Abstract 486: Prophylactic cranial irradiation (PCI) significantly decreases risk of brain metastases in patients with bulky, higher stage small-cell urothelial cancer.
First Author: Seungtaek Choi, MD


BOARD L14
Abstract 487: Utilization and outcomes of adjuvant radiation therapy after cystectomy for urothelial carcinoma.
First Author: Kenneth Verlage, MD


BOARD L15
Abstract 488: Twenty-eight-day prophylaxis with apixaban after radical cystectomy: Early results in safety.
First Author: Taha Anwar, MD


BOARD L16
Abstract 489: Urologic malignancies: A comparison of outcomes after index surgery between academic and community hospitals.
First Author: Jamil Syed, MD


BOARD L17
Abstract 490: A comprehensive assessment of postoperative complications in female patients undergoing robot versus open radical cystectomy.
First Author: Vikram Narayan, M.D.


BOARD L18
Abstract 491: The impact of pathologic downstaging with neoadjuvant chemotherapy on survival of patients with muscle-invasive bladder cancer.
First Author: Alberto Martini


BOARD L19
Abstract 492: Robot-assisted radical cystectomy (RARC) versus open radical cystectomy (ORC): Oncological outcomes in 469 patients with a mean follow-up of five years.
First Author: Kassem Faraj, MD


BOARD L20
Abstract 511: Cross-trial comparison of taxane versus non-taxane combination chemotherapy regimens for advanced penile cancer (APC): A systematic review.
First Author: Esmail Al-Ezzi, MBBS


BOARD L21
Abstract 512: Predicting overall survival (OS) in patients (pts) with penile squamous cell carcinoma (PSCC) undergoing regional lymph node dissection (LND) ± multimodal therapy.
First Author: Andrea Necchi, MD, MD


BOARD L22
Abstract 513: Development and validation of a DNA methylation panel for the prediction of outcome in node-positive penile squamous cell carcinoma after lymphadenectomy.
First Author: Yao Zhu


BOARD M1
Abstract 514: Penile and uterine cervical squamous cell carcinomas: A comparative genomic profiling study.
First Author: Joseph Jacob


BOARD M2
Abstract 515: PD-L1 and p16 expression in penile squamous cell carcinoma from an endemic region.
First Author: Mateus De Bacco, MD


BOARD M3
Abstract 516: Comprehensive and epidemiological characterization of urachal adenocarcinoma: A pan-Canadian collaboration.
First Author: Belkaid Wiam, PhD


BOARD M4
Abstract 517: A phase II study of ribociclib in men with unresectable, incurable teratoma with recent progression.
First Author: Daniel Castellano, MD


BOARD M5
Abstract 518: Clinical features and outcomes of secondary somatic malignancy (SSM) arising from teratoma in late relapse germ cell tumor (GCT).
First Author: Nathan Wong, MD


BOARD M6
Abstract 519: Persistence of platinum in semen of cisplatin-treated survivors of advanced testicular cancer.
First Author: Eoghan Malone, MBBCh


BOARD M7
Abstract 520: Risk factors for venous thromboembolism (VTE) during chemotherapy in patients with germ cell tumors (GCT).
First Author: Cassia Griswold, PharmD


BOARD M8
Abstract 521: Patient-reported psychosocial distress in adolescents and young adults with germ cell tumors.
First Author: Maryam Soleimani, MD


BOARD M9
Abstract 522: Survival and toxicity outcomes in patients age 40 or older with relapsed metastatic germ cell tumors (mGCT) treated with high-dose chemotherapy (HDCT) and autologous peripheral-blood stem cell transplant (PBSCT).
First Author: Nabil Adra, MD, BS


BOARD M10
Abstract 523: Excellent outcomes in bilateral testicular germ cell tumors over four decades.
First Author: Ning-Ning Lu, Dr.


BOARD M11
Abstract 524: Postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) in patients with testis cancer in the salvage setting.
First Author: Peter Albers, MD


BOARD M12
Abstract 525: Increasing adipose burden in young men with metastatic testicular cancer following front-line cytotoxic chemotherapy.
First Author: Karan Arora, MD


BOARD M13
Abstract 526: Validation of plasma miR-371a-3p expression in patients with metastatic and early stage germ cell tumor.
First Author: Lucia Nappi, MD, PhD


BOARD M14
Abstract 527: Predicting vital retroperitoneal residual tumors of metastatic testicular tumor patients after chemotherapy using radiomics.
First Author: Tim Nestler, MD


BOARD M15
Abstract 528: Seminomatous germ cell tumors are heterogenic and metastasis can be predicted based on a gene signature of the tumor invasive front.
First Author: Tim Nestler, MD


BOARD M16
Abstract 529: The features and management of late relapse of non-seminomatous germ cell tumors: The Royal Marsden Experience.
First Author: Robert Huddart, MBBS, MRCP, FRCR, PhD


BOARD M17
Abstract 530: Clinical outcomes of minimally invasive retroperitoneal lymph node dissection and single dose carboplatin for clinical stage IIa seminoma.
First Author: Robert Huddart, MBBS, MRCP, FRCR, PhD


BOARD M18
Abstract 531: Clinical features and outcomes of secondary somatic malignancy (SSM) associated with primary mediastinal nonseminomatous germ cell tumors (PM-NSGCT).
First Author: Lucas Dean


BOARD M19
Abstract 532: Genomic features of metastatic testicular sex cord stromal tumors.
First Author: Andrea Necchi, MD, MD


BOARD M20
Abstract 533: Clinical features and outcomes of tumor lysis syndrome in patients with genitourinary cancers.
First Author: Jue Wang, MD


BOARD M21
Abstract 534: Survival rates after retroperitoneal lymph node dissection (RPLND) for testicular seminoma.
First Author: Alexandra Tabakin, MD


BOARD M22
Abstract 535: Intraoperative and early postoperative outcomes in post-chemotherapy retroperitoneal lymphadenectomy using validated grading classifications.
First Author: Eric Umbreit, MD


BOARD N1
Abstract 536: Role of robot assisted retroperitoneal lymph node dissection in metastatic malignant mesothelioma of the tunica vaginalis: Case series.
First Author: Kassem Faraj, MD


BOARD N2
Abstract 537: Programmed death-ligand 1 (PD-L1) expression in pheochromocytoma.
First Author: Yasuhiro Hashimoto


BOARD N3
Abstract TPS493: A phase II, randomized study of nivolumab (nivo) or nivo plus BMS-986205 with or without intravesical Bacillus Calmette-Guerin (BCG) in BCG-unresponsive, high-risk, non-muscle invasive bladder cancer (NMIBC): CheckMate 9UT.
First Author: Noah Hahn, MD


BOARD N4
Abstract TPS494: A phase II, multicenter, single-arm trial of CV301 plus atezolizumab (Atezo) in locally advanced (unresectable) or metastatic urothelial cancer (UC).
First Author: Guru Sonpavde, MD


BOARD N5
Abstract TPS495: TROPHY-u-01: A phase II open-label study of sacituzumab govitecan (IMMU-132) in patients with advanced urothelial cancer after progression on platinum-based chemotherapy and/or anti-PD-1/PD-L1 checkpoint inhibitor therapy.
First Author: Scott Tagawa, MD, MS


BOARD N6
Abstract TPS496: ATLAS: A phase II open-label study of rucaparib in patients with locally advanced or metastatic urothelial carcinoma (mUC).
First Author: Petros Grivas, MD, PhD


BOARD N7
Abstract TPS497: EV-301: Phase III study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC).
First Author: Daniel Petrylak, MD


BOARD N8
Abstract TPS498: Phase II study of sitravatinib in combination with nivolumab in patients with advanced or metastatic urothelial carcinoma (UC) after checkpoint inhibitor therapy (CIT).
First Author: Gurjyot Doshi, MD


BOARD N9
Abstract TPS499: A phase III, randomized, open-label, multicenter, global study of first-line (1L) durvalumab in combination with standard of care (SoC) chemotherapy and durvalumab in combination with tremelimumab and soc chemotherapy versus soc chemotherapy alone in patients with unresectable locally advanced or metastatic urothelial cancer (UC).
First Author: Matt Galsky, MD, FASCO


BOARD N10
Abstract TPS500: A phase III, randomized, open-label, multicenter, global study of durvalumab and bacillus calmette-guérin (BCG) versus BCG alone in high-risk, BCG-naïve non-muscle-invasive bladder cancer (NMIBC) patients (POTOMAC).
First Author: Maria De Santis, MD


BOARD N11
Abstract TPS501: A phase I-II study to evaluate safety and efficacy of the combination of niraparib plus cabozantinib in patients with advanced kidney/urothelial carcinoma.
First Author: Albert Font Pous


BOARD N12
Abstract TPS502: Keynote-676: Phase 3 study of bacillus calmette-guerin (BCG) with or without pembrolizumab (pembro) for high-risk (HR) non–muscle invasive bladder cancer (NMIBC) that is persistent or recurrent following BCG induction.
First Author: Ashish Kamat, MD


BOARD N13
Abstract TPS503: Impact of the combination of durvalumab (MEDI4736) plus olaparib (AZD2281) administered prior to surgery in the molecular profile of resectable urothelial bladder cancer: NEODURVARIB Trial.
First Author: Juan Francisco Rodriguez-Moreno, MD, PhD


BOARD N14
Abstract TPS504: Alliance A031501: Phase III randomized adjuvant study of MK-3475 (pembrolizumab) in muscle-invasive and locally advanced urothelial carcinoma (MIBC) (AMBASSADOR) versus observation.
First Author: Andrea Apolo, MD


BOARD N15
Abstract TPS538: Phase II study of apatinib: A novel VEGFR inhibitor in pretreated patients with metastatic penile cancer.
First Author: Sheng Zhang, MD


BOARD N16
Abstract TPS539: P3BEP (ANZUP 1302): An international randomized phase III trial of accelerated versus standard BEP chemotherapy for adult and pediatric male and female patients with intermediate and poor-risk metastatic germ cell tumors (GCTs).
First Author: Alison Zhang, MBBS, FRACP, MMedSc